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Dr Antoon E. M. R. Lerut (Leuven, Belgium). I have no finan-
cial disclosures.
This was an excellent presentation on a topic that indeed has not
been investigated thoroughly until this presentation. The conclu-
sions are first that indeed you can obtain long-term survival and dis-
ease-free survival in 1 of 4 patients. Second, patients with more
than 7 positive lymph nodes have a poor prognosis and dismal sur-
vival, and finally, adjuvant chemotherapy, at least one cycle, does
not seem to be of any benefit.The Journal of Thoracic and CaI have 2 questions. As you said, a strong negative prognostic fac-
tor is the presence of more than 7 positive nodes. However, these
data are retrieved from pathologic, that is, postoperative analysis.
The question, of course, arises whether it is possible to identify
such negative factor before surgery when reassessing the effect
of induction chemotherapy, eventually avoiding unnecessary sur-
gery in those patients. In this respect, our group some years ago
published the findings of PET scan after induction therapy, indicat-
ing that persistent positive lymph node involvement on PET scan is
a strong negative prognostic factor.
My specific question here is this: did you make such an effort to
correlate these pathologic findings of more than 7 positive nodes
with your findings obtained at baseline clinical staging and also
after restaging your patients after induction? If so, was there any
positive correlation?
Dr Stiles.That is a great question. I think everybody would like to
know how to find out who is going to do poorly. Right now, unfor-
tunately, we are not good at it. Our group has also looked at PET
scan, and we found significant improvements in survival with greater
than a 50% reduction in maximum standardized uptake value. One
point to note is that 11 of 13 patients who had a complete response
on PET in that group still had persistent disease. I think the restaging
issue works both ways. It identifies patients who have advanced dis-
ease, but some people also use it as justification not to operate based
on perceived complete response. We are not able to predict that either
with PET or with our clinical assumptions. In this patient population,
40% had improved disease or a complete response by clinical criteria;
however, they clearly did not have a complete response on pathologic
criteria. The question of determining the patient population with more
than 7 lymph nodes is a good one. We are not able to distinguish that
well on PET scan, unfortunately.
Dr Lerut. Not the exact numbers, that is correct. However, our
experience, and also, I believe, a South Korean study, showed that
if you have more than 3 individual spots on the PET scan, the prog-
nosis indeed is very dismal; as you showed, below 15.
Dr Stiles. Yes, sir.
Dr Lerut. My second question goes to the issue of the 3-field
lymphadenectomy as compared with 2-field lymphadenectomy.
What were your indications for the 2-field versus the 3-field lym-
phadenectomy? Two thirds of the patients had a 3-field and one
third a 2-field lymphadenectomy. You did not explain this. Also,
you made the point that about 30% of the patients had positive no-
des along the recurrent laryngeal nerve chain. We have to consider
the fact that this chain lies in part in the chest and in part in the neck.
Thus, the question is, what precisely was the additional yield spe-
cifically from the cervical field, in particular given the fact that it
adds to the morbidity, when adding the third field? Was there
any survival benefit from 3-field lymphadenectomy when you com-
pare it with your en bloc resection plus 2-field lymphadenectomy?
Dr Stiles. We were unable to show a survival benefit between
the 3-field and the 2-field lymphadenectomies in this patient popu-
lation. In terms of who gets it, all the patients with middle and upper
third tumors obviously get the third field, but we are a bit more se-
lective with the lower and gastroesophageal junction tumors. We
may be a bit less aggressive in patients who tend to have more co-
morbidities, particularly respiratory comorbidities, or those in
whom we are worried about recurrent nerve injury. Sometimes
with very big or obese patients, we will also be a little less likely
to pursue the third field.rdiovascular Surgery c Volume 139, Number 2 393
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SDr Lerut. Could you tell us something about the additional
yield specifically from what you found in the neck?
Dr Stiles. Dr Altorki could probably comment better. My per-
sonal take is that most of the recurrent nodes that we get are from
the chest and it is rare that we get the ones from the neck.
Dr Lerut. There are studies, mainly from Japan, showing that
a positive node at the brachiocephalic trunk is like a sentinel
node. In other words, if the nodes there are negative, it is useless
to do a cervical lymphadenectomy, because the chances of having
positive lymph nodes are below 10%, but if they are positive it is
seen as an indication to go further and do the third field. That is
why I asked that question.
Dr Stiles. Yes, sir, I agree. I think an important point to make,
though, is that a lot of these nodes in the recurrent chain can be
reached from the chest. A lot of surgeons who are doing an Ivor
Lewis procedure can get to that area and at least sample the nodes
to better stage the patients, as you suggested previously.
Dr Bryan F.Meyers (St Louis, Mo). This is a unique population
of patients, because you are picking them based on one character-
istic of their pathologic stage. You are eliminating patients who re-
ceived induction therapy and progressed on a macroscopic level
during induction therapy. You are eliminating patients who under-
went induction therapy and then had a decline in their performance
status, and you chose not to operate on them. You did not say it, but
I suspect that there are some patients who undergo exploration after
induction therapy and do not undergo resection, and those patients
also did not make it into this article. So, within the limits of the very
selected group of patients, I think you have a solid list of predictors
of poor or better outcome. However, I do not know whether it can
inform the decision about whether to operate when you suspect per-
sistent lymph nodes because that detection of persistent lymph no-
des after induction therapy is notoriously inaccurate.
The other thing I would ask you to comment on, because it is
unique, is that your induction therapy for about 20 years now has
been chemotherapy alone, and that is probably different from
most of the members of the audience. Please explain why you
started and then stuck with that regimen.
Dr Stiles. Thank you for the questions. Again, I thank both you
gentlemen for reviewing the paper on late notice.
I agree with your statement that this does not include all of those
patients. We did not capture all the patients in our database who fell
out for whatever reason, whether performance status, progression
of disease, or exploration without resection, although I think that
that number is very low. Our general point is that clearly people
can identify the patients who dramatically progress, whether the
progression is indicated by bulky lymph nodes or systemic metas-
tases. I think the issue that sometimes physicians wrestle with is
what to do if somebody gets a biopsy after induction with persistent
positive nodes, particularly if they may be celiac or recurrent laryn-
geal. Maybe we should not operate on these patients. As we have
shown, survival can be achieved in a significant portion, but, again,
it is a very selected group, a retrospective study. We tend to offer
surgery to almost everybody except for those who progress with
systemic disease or significant bulky disease in the neck.
Regarding chemotherapy versus chemoradiation, we have writ-
ten about it a lot. Everybody in the room has probably written and
read about it. To us the jury is still out on what is better, what is not.
Certainly more people experience a pCR with chemotherapy and394 The Journal of Thoracic and Cardiovascular Surgradiation therapy. Whether that translates into long-term survival,
particularly for adenocarcinoma, is unclear. I do not think that there
are good data to support that one way or another. Most patients with
this disease have systemic failure and die of systemic disease.
Therefore, to us, adding radiation therapy to the en bloc esophagec-
tomy and extensive lymphadenectomy does not add a lot to the lo-
cal treatment of this disease.
Dr Altorki. I just want to make a comment about preoperative
chemotherapy. We have learned some good lessons from preoper-
ative chemotherapy in lung cancer. I think 2 and up to 4 cycles of
chemotherapy can be given with a single-digit rate of disease pro-
gression. What I see more often is if protracted (3 or 4 months’
worth) chemoradiation is given, and then it is necessary to wait an-
other month, I tend to see more patients who progress under those
circumstances. Two to 4 cycles of chemotherapy is usually associ-
ated with very low disease progression during the treatment.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Dr Altorki, on
the basis of your data, if you identify someone in that high-risk
group, and I know you made the comment that you do not think
chemotherapy adjuvantly adds anything, but if someone has
more than 7 nodes now, what do you do? If the patients are fit,
do you think that they should be subjected to second-line or
some other cocktail?
Dr Altorki. That is a great question. I do not really know how to
pick those individuals that will be more or less than 7, if 7 is the
number. Toni mentioned 2 or 3 different areas of uptake on the
PET scan, and I would submit to you that if I ever saw that, I would
probably not operate, but that is not what you usually see. What I
try to do is restage the patients after 2 cycles, and if it seems that
they have had a favorable biological response based on the PET cri-
teria, then I add 2 additional cycles. I try to get them most of their
chemotherapy up front because I know that they are not going to be
able to take it on the back end.
DrMeyers.You said that you would restage them after 2 cycles.
Do you do endoscopic ultrasound fine needle aspiration or do you
do a PET scan?
Dr Altorki. I use PET and computed tomographic scans. I think
the data on endoscopic ultrasound and how successful fine needle
aspiration is in that setting are questionable. The PET scan is
quicker and, to my mind, even a little bit more informative.
Dr Frank C. Detterbeck (New Haven, Conn). Your survival
was quite good for those patients who have nodal disease after
esophagectomy. You do a fairly extensive lymph node dissection.
Do you think that having a few nodes positive after a very extensive
lymph node dissection is a somewhat different group of patients
than, say, if you do not do a very extensive lymph node dissection
and you have a node-positive patient? Do you think that explains
why your results are so good?
Dr Altorki. Differently stated, if I may, I think that the question
goes to what is the influence of the total lymph nodes resected on out-
come. This particular work that Brendon did does not answer that
question, because everybody had a lot of nodes resected. We have
just published in the Annals of Surgery a larger series in which there
were equal numbers of patients on each side of that divide. Clearly,
at least in our work, and I know that is not universally accepted, the
more nodes you took, the better off you were in terms of survival. If
you were truly node-negative, the difference was tiny, but if you
were node-positive, the difference was more statistically significant.ery c February 2010
